Compare OPTT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTT | CRDL |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.9M | 97.3M |
| IPO Year | 2006 | 2017 |
| Metric | OPTT | CRDL |
|---|---|---|
| Price | $0.37 | $0.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.50 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 6.9M | 365.5K |
| Earning Date | 03-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,861,000.00 | N/A |
| Revenue This Year | $39.58 | N/A |
| Revenue Next Year | $168.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $0.29 | $0.77 |
| 52 Week High | $0.90 | $1.59 |
| Indicator | OPTT | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 44.95 |
| Support Level | $0.30 | $0.95 |
| Resistance Level | $0.56 | $1.09 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 14.64 | 35.77 |
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.